GSK licensed HS-20093, a B7-H3 targeted ADC with topoisomerase inhibitor payload, from Hansoh Pharma. GSK paid $185M upfront with up to $1.525B in success-based milestones plus tiered royalties. GSK obtained exclusive worldwide rights excluding Greater China. This was GSK's second ADC deal with Hansoh in two months.